FindTrial
Sign In

Effect of Low dose platelet transfusion in adult cancer patients.

To analyse the efficacy of low dose prophylactic platelet transfusion in adult oncology patients with thrombocytopenia.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/11/047715
Enrollment
30
Registered
2022-11-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

None listed

Sponsors

RELIABLE CORPORATION
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patient with age >18 years. 2) Patients fulfilling the institutional guidelines for prophylactic platelet transfusion.

Exclusion criteria

Exclusion criteria: 1)Patients on drugs known to cause thrombocytopenia or platelet dysfunction eg. Vancomycin, Amphotericin B, Aspirin. 2) Patientâ??s having immune and non-immune causes of platelet refractoriness like fever, sepsis, bleeding, DIC, splenomegaly.

Design outcomes

Primary

MeasureTime frame
To determine the efficacy of low dose SDP transfusions in adult oncology patients requiring prophylactic platelet transfusions by checking Corrected count Increment(CCI) 10-60 minutes post transfusion.Timepoint: 3 months—

Secondary

MeasureTime frame
To assess the frequency and the types of adverse transfusion reactions associated with platelet transfusion.Timepoint: 3 months—

Countries

India

Contacts

Public ContactDr Priti D Desai

Tata Memorial Hospital

survebhagyashri@rediffmail.com022-24177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026